12:00 AM
 | 
Oct 12, 2009
 |  BC Week In Review  |  Company News  |  Deals

Cytopia, YM BioSciences deal

Cytopia's lead candidate is CYT997, a small molecule tubulin inhibitor and vascular targeting agent that is in Phase II trials to treat glioblastoma multiforme (GBM) and relapsed or refractory multiple myeloma (MM). The deal also gives...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >